Correlation Between NYSE Composite and ENDRA Life

Can any of the company-specific risk be diversified away by investing in both NYSE Composite and ENDRA Life at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and ENDRA Life into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NYSE Composite and ENDRA Life Sciences, you can compare the effects of market volatilities on NYSE Composite and ENDRA Life and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of ENDRA Life. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and ENDRA Life.

Diversification Opportunities for NYSE Composite and ENDRA Life

-0.59

Correlation Coefficient

NYSE Composite  ENDRA Life

Excellent diversification

The 3 months correlation between NYSE and ENDRA is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and ENDRA Life Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ENDRA Life Sciences and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with ENDRA Life. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ENDRA Life Sciences has no effect on the direction of NYSE Composite i.e., NYSE Composite and ENDRA Life go up and down completely randomly.

Pair Corralation between NYSE Composite and ENDRA Life

Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.07 times more return on investment than ENDRA Life. However, NYSE Composite is 15.04 times less risky than ENDRA Life. It trades about -0.06 of its potential returns per unit of risk. ENDRA Life Sciences is currently generating about -0.12 per unit of risk. If you would invest  2,001,587  in NYSE Composite on September 12, 2024 and sell it today you would lose (12,484) from holding NYSE Composite or give up 0.62% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

NYSE Composite  vs.  ENDRA Life Sciences

Pair Trading with NYSE Composite and ENDRA Life

The main advantage of trading using opposite NYSE Composite and ENDRA Life positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, ENDRA Life can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ENDRA Life will offset losses from the drop in ENDRA Life's long position.

The idea behind NYSE Composite and ENDRA Life Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.